AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01314911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Study NCT01314911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
Study NCT03911310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-11
Description: \[18F\]PSMA-11 PET/CT
Study NCT03911310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [18F]PSMA-11
Description: \[18F\]PSMA-11 PET/CT
Study NCT03911310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-11
Description: \[68Ga\]PSMA-11 PET/CT
Study NCT03911310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]PSMA-11
Description: \[68Ga\]PSMA-11 PET/CT
Study NCT02234856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysterectomy trainer
Description: In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
Study NCT00479895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Description: Pre-oxygenated HBOC-201
Study NCT03998813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Locoregional analgesia by femoral triangle catheterization
Study NCT03998813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Tissue infiltration
Study NCT02824172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cast immobilization group
Description: Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
Study NCT02824172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete sport rest.
Description: Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
Study NCT03914846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound with elastography
Study NCT04386915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
Study NCT01798823 — intervention group
Intervention type: PROCEDURE
Intervention: History, physical, LF, SPT, blood sample, FeNO, EBC.
Description: Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
Study NCT04589286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pack Health's Digital Life Coaching (DLC)
Description: Pack Health smartphone-based DLC platform
Study NCT04589286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Handouts
Description: Generic wellness-related electronic handouts
Study NCT04589286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Handouts
Description: Generic wellness-related electronic handouts
Study NCT03904095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psoas Compartment Block Group (GROUP I)
Description: Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03904095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block ( Group II)
Description: ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03904095 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (GROUP III)
Description: Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT04307680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peritron perineometer
Description: Perineometry will be used to assess quality of each observed treatment modality.
Study NCT00182260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton Pump Inhibitors
Study NCT00182260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen Fundoplication
Study NCT02420353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
Study NCT02420353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
Study NCT04356313 — intervention group
Intervention type: DEVICE
Intervention: GORE® EXCLUDER® Iliac Branch Endoprosthesis
Description: Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
Study NCT02957331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT04275349 — intervention group
Intervention type: DRUG
Intervention: Xingnaojing injection within 24 hours of symptom onset
Description: intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Study NCT00624078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Description: three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
Study NCT02333968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management support
Description: The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
Study NCT02234986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 250 mg oral dose, QD for 28 day cycles
Study NCT01928576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT01928576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Study NCT01928576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01928576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 300
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT03072082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT01621958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated perturbation training
Description: One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
Study NCT01621958 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal perturbation training
Description: One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
Study NCT00737061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adiana Transcervical Sterilization System
Description: Implantation of silicone matrix in fallopian tubes
Study NCT03688789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone supplementation
Description: * Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30
Study NCT04149262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
Study NCT04149262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid
Description: Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
Study NCT04149262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 640G pump
Description: MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
Study NCT00610675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 50081
Description: One tablet daily
Study NCT04126473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
Study NCT04126473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: CFTR potentiator
Study NCT00933062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: 2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
Study NCT00933062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
Study NCT01943279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Follow-up (RFU)
Description: Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
Study NCT01943279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-up (SFU)
Description: Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
Study NCT01546220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study NCT03671083 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
Study NCT02117050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
Study NCT03849560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grippol® Quadri
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
Study NCT03849560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol® Plus, trivalent (Yamagata lineage)
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
Study NCT03849560 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol® Plus, trivalent (Victoria lineage)
Description: Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
Study NCT04386915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
Study NCT04166162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention Motivational Interviewing (BIMI) Intervention
Description: BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
Study NCT04166162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tomando Buenas Decisiones (TBD) Intervention
Description: The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
Study NCT04166162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Development Strategy (SDS) Intervention
Description: SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
Study NCT00187317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training (exercise)
Description: Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
Study NCT00874614 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultratrace® Iobenguane I131
Description: Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
Study NCT03988959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection of mucoeidermoid carcinoma
Description: Surgical resection parotid with preservation of facial nerve
Study NCT01611454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPF thyroid collar
Description: Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
Study NCT01611454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 0.5mm lead equivalent thyroid collar
Description: Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
Study NCT00821067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
Study NCT00821067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
Study NCT00531986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-Monotherapy
Description: Patients on triple HAART will be switched to LPV/r-monotherapy
Study NCT00531986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Patients will continued their current HAART
Study NCT01461057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
Study NCT01461057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 on Day 1 of each cycle
Study NCT01461057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: loading dose of 840 mg, then 420 mg once every three weeks
Study NCT01461057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg once every three weeks
Study NCT01461057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
Study NCT04166162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTC Training Session
Description: BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
Study NCT00187317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flexibility and relaxation exercise
Description: 30-minute sessions, three times per week for six weeks.